What are the contraindications to Dasatinib?

Dasatinib (Dasatinib) is an important targeted therapy used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Although Dasatinib (Startaxel) has shown significant efficacy in the treatment of leukemia, it also has some contraindications, that is, using Dasatinib (Startaxel) in the following situations may bring additional risks, and patients need to avoid or reduce the use of this drug.

1. Allergic reaction: If the patient has an allergic reaction, such as skin rash, urticaria, dyspnea, etc., to Dasatinib (Startaxel) or any of its ingredients, then the use of dasatinib (Startaxel) may cause a serious allergic reaction, so the use of this drug should be avoided.

2. Serious cardiovascular disease: Dasatinib (Startax) may cause cardiotoxicity, including arrhythmia, angina, heart failure, etc. Therefore, for patients with existing serious cardiovascular diseases, such as myocardial infarction, cardiomyopathy, heart failure, etc., dasatinib should be avoided.

3. Severe liver function damage: Dasatinib (Startase) may cause abnormal liver function, including elevated liver enzymes, jaundice, etc. Therefore, for patients with severely impaired liver function, such as hepatic insufficiency, cirrhosis, etc., the use of dasatinib (Startase) should be avoided.

4. Pregnancy and lactation: Dasatinib (Startase) may cause damage to the fetus, so pregnant women should avoid using Dasatinib (Startase) during pregnancy. In addition, dasatinib may be excreted in breast milk, so breast-feeding women should avoid its use.

5. Pulmonary arterial hypertension (PAH): Dasatinib (Startase) may cause pulmonary arterial hypertension, and patients may experience symptoms such as dyspnea and chest pain during treatment. Therefore, the use of dasatinib should be avoided in patients who have pulmonary hypertension or are at risk for pulmonary hypertension.

6. Combined use with contraindicated drugs: Dasatinib (Startase) may have serious interactions with some contraindicated drugs, increasing the risk of side effects. Therefore, patients should inform their doctors about other medications they are taking before taking dasatinib (Startase) to avoid adverse drug interactions.

7. Other serious underlying diseases: For patients with other serious underlying diseases, such as severe renal insufficiency, severe respiratory diseases, etc., the use of Dasatinib (Startase) should be carefully considered, and the decision whether to use this drug should be made under the guidance of a doctor.

In general, Dasatinib (Startax) is an important anti-cancer drug, but there may be some contraindications during use. Patients need to make reasonable medication choices under the guidance of a doctor. Doctors should decide whether to use Dasatinib (Dasatinib) based on the patient's specific conditions after assessing the patient's condition and making a comprehensive assessment. They should closely monitor the patient's health status during the treatment process and adjust the treatment plan in a timely manner to ensure the safety and effectiveness of the treatment.